Tirzepatide (Zepbound): A separate GLP-1/GIP dual agonist with comparable or superior efficacy in SURMOUNT-1 (N=2,539, 72 weeks: 20.9% mean weight loss at 15 mg) [15], and potentially different insurance coverage depending on your plan In SURMOUNT-1, 89.1% of tirzepatide 15 mg participants achieved at least 5% weight loss versus 34.4% on placebo [15]
Sunlight is the primary source of ultraviolet (UV) radiation, a major risk factor for all skin cancers
Frequency: Administered once or twice per week due to its extended half-life (around 6-8 days)
The reality is that for many people, obesity represents a biological condition that requires pharmacological management just like any other chronic disease
Data sources, searches and study selection The writing group members were appointed by the ADA and EASD
To analyze the interaction between the factors, multiple linear regression was performed